NFKB1 and central nervous system cancer: Bexarotene treatment in C6 glioma cells impedes NF-κB activation by amplifying PPARγ expression, leading to the regulation of apoptosis, DNA damage, and ROS production, among other processes, consequently exerting anti-proliferative and cytotoxic effects [54].